Active Filter(s):
Details:
STORM has identified novel, potent and selective first-in-class inhibitors of METTL3 that are orally bioavailable and show pronounced anti-tumour efficacy in animal models of AML, as well as solid tumours. This publication utilises STM2457, an earlier compound than STC-15.
Lead Product(s): STM2457
Therapeutic Area: Oncology Product Name: STM2457
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2021